Bloomage Biotech(SH:688363) Jin Rong Jie·2026-01-19 01:55Core Insights - The announcement of the first batch of "Biomanufacturing Pilot Capability Construction Platform List" by the Ministry of Industry and Information Technology highlights Huaxi Biological Technology (Tianjin) Co., Ltd. as a leading player, achieving the highest "five-star" rating and being one of only five such units in the country [1] - The recognition emphasizes the importance of pilot platforms in bridging the gap between research and industrialization in biomanufacturing, addressing the low technology transfer rate in China compared to developed countries [1][2] Group 1: Company Achievements - Huaxi Biological has invested over 3 billion yuan to create the world's largest synthetic biology pilot transformation platform, featuring 64 pilot production lines across a 40,000 square meter facility [2] - The platform supports the scale-up of six categories of bioactive substances, serving multiple strategic emerging industries including pharmaceuticals, cosmetics, and functional foods [2][3] Group 2: Industry Context - The pilot platform is crucial for overcoming the challenges of scaling up from laboratory to industrial production, addressing issues such as process optimization, quality control, and cost accounting [2] - The Chinese government aims to cultivate over 20 biomanufacturing pilot platforms by 2027, recognizing biomanufacturing as a key aspect of the Fourth Industrial Revolution, with a projected global market size exceeding $390 billion by 2030 [3][4] Group 3: Collaborative Efforts - The pilot transformation platform is designed to be an industry-level infrastructure, providing comprehensive services to universities and startups, thus promoting the integration of government, industry, academia, research, finance, and application [4] - Huaxi Biological aims to enhance the overall capabilities of China's biomanufacturing sector through collaboration and the development of a robust platform ecosystem [4]